Elicio Therapeutics (ELTX) Other Non-Current Assets (2021 - 2026)
Elicio Therapeutics' (ELTX) quarterly Other Non-Current Assets came in at $995000.0 in Q1 2026, up 42.55% YoY from $698000.0 in Q1 2025, and up 29.22% on a QoQ basis from $770000.0 in Q4 2025.
Elicio Therapeutics (ELTX) Other Non-Current Assets (2021 - 2026) Analysis & Trends
Elicio Therapeutics (ELTX) has 6 years of Other Non-Current Assets data on file, last reported at $995000.0 in Q1 2026.
- Quarterly Other Non-Current Assets rose 42.55% year-over-year to $995000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $995000.0 (up 42.55% YoY) and the FY2025 annual result came in at $770000.0, up 28.33% from the prior year.
- Other Non-Current Assets rose to $995000.0 in Q1 2026, from $770000.0 in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $2.8 million in Q2 2023 to a low of $75000.0 in Q3 2022.
- A 5-year average of $973882.4 and a median of $698000.0 in 2025 frame the typical range for Other Non-Current Assets.
- Annual changes were most pronounced in 2023 — Other Non-Current Assets soared 3155.81% — and 2024, when it tumbled 78.57%.
- Tracing ELTX's Other Non-Current Assets over 5 years: stood at $617000.0 in 2022, then soared by 353.81% to $2.8 million in 2023, then plunged by 78.57% to $600000.0 in 2024, then advanced by 28.33% to $770000.0 in 2025, then gained by 29.22% to $995000.0 in 2026.
- The last three Other Non-Current Assets figures came in at $995000.0 (Q1 2026), $770000.0 (Q4 2025), and $800000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | Elicio Therapeutics | 58.41 Mn | 34.91 Mn | - | 825,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 825,000.00 |
| Mar 31, 2026 | 995,000.00 |
| Dec 31, 2025 | 770,000.00 |
| Sep 30, 2025 | 800,000.00 |
| Jun 30, 2025 | 700,000.00 |
| Mar 31, 2025 | 698,000.00 |
| Dec 31, 2024 | 600,000.00 |
| Sep 30, 2024 | 600,000.00 |
| Jun 30, 2024 | 690,000.00 |
| Mar 31, 2024 | 2.70 Mn |
| Dec 31, 2023 | 2.80 Mn |
| Sep 30, 2023 | 683,000.00 |
| Jun 30, 2023 | 2.80 Mn |
| Mar 31, 2023 | 864,000.00 |
| Dec 31, 2022 | 617,000.00 |
| Sep 30, 2022 | 75,000.00 |
| Jun 30, 2022 | 86,000.00 |
| Mar 31, 2022 | 78,000.00 |
| Dec 31, 2021 | 106,000.00 |
| Sep 30, 2021 | 33,000.00 |